

Fengchao Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9590545/publications.pdf>

Version: 2024-02-01

7
papers

241
citations

1307594

7
h-index

1720034

7
g-index

7
all docs

7
docs citations

7
times ranked

413
citing authors

#	ARTICLE	IF	CITATIONS
1	TGF- β 1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial-mesenchymal transition and cancer stem cell phenotypes. <i>Cancer Letters</i> , 2015, 359, 288-298.	7.2	88
2	MiR-155 targets TP53INP1 to regulate liver cancer stem cell acquisition and self-renewal. <i>FEBS Letters</i> , 2015, 589, 500-506.	2.8	52
3	MiR-155 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells through the activation of PI3K/SKG3/ β -catenin signaling pathways. <i>Oncotarget</i> , 2016, 7, 66051-66060.	1.8	27
4	PIK3C3 regulates the expansion of liver CSCs and PIK3C3 inhibition counteracts liver cancer stem cell activity induced by PI3K inhibitor. <i>Cell Death and Disease</i> , 2020, 11, 427.	6.3	26
5	Secreted protein acidic and rich in cysteine promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells and acquisition of cancerstem cell phenotypes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1860-1868.	2.8	17
6	The role of CD133 in hepatocellular carcinoma. <i>Cancer Biology and Therapy</i> , 2021, 22, 291-300.	3.4	16
7	Prolonged inhibition of class I PI3K promotes liver cancer stem cell expansion by augmenting SGK3/GSK-3/ β -catenin signalling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 122.	8.6	15